BCL9L and metastatic neoplasm: Considering that Cal29 originates from a muscle-invasive metastatic bladder carcinoma and T24 from a non-muscle invasive and non-metastatic disease, it can be hypothesised that BCL9L/β-catenin signalling plays a crucial role later in the progression of BC.